Intravenous versus intraperitoneal Magnesium Sulfate in laparoscopic sleeve gastrectomy
Not Applicable
Completed
- Conditions
- Digestive Systempain
- Registration Number
- PACTR201801002944228
- Lead Sponsor
- Tanta University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
adult patients of both sexes,
aged 18-60 ,
ASA physical status I ¿II
scheduled for elective laparoscopic bariatric surgeries
Exclusion Criteria
patient refusal,
severe respiratory or cardiac disorders, hepatic or renal insufficiency,
allergy to any of the study drugs,
pregnancy or breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain magnesium sulfate's effect on hemodynamic stability during laparoscopic sleeve gastrectomy?
How does intraperitoneal magnesium sulfate compare to intravenous administration in postoperative pain management for bariatric surgery?
Are there specific biomarkers that predict better outcomes with intravenous versus intraperitoneal magnesium sulfate in metabolic surgery?
What are the potential adverse events associated with magnesium sulfate use in laparoscopic sleeve gastrectomy and how are they managed?
What combination therapies or alternative drugs show similar hemodynamic and analgesic effects as magnesium sulfate in bariatric procedures?